Article info

Download PDFPDF
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

Authors

  1. Correspondence to Dr Michael Bonelli, Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; michael.bonelli{at}meduniwien.ac.at
View Full Text

Citation

Mrak D, Simader E, Sieghart D, et al
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

Publication history

  • Received March 31, 2022
  • Accepted August 1, 2022
  • First published August 17, 2022.
Online issue publication 
October 18, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.